MedTrace Logo

Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis

NCT02431429 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2019-03-04

No results posted yet for this study

Summary

This study is a Phase 4, open-label, single group study in which at least 55 evaluable adult male patients undergoing miltefosine treatment for mucocutaneous leishmaniasis will provide semen samples for spermiogram analysis of sperm parameters.

Conditions

  • Mucocutaneous Leishmaniasis

Interventions

DRUG

Miltefosine

Sponsors & Collaborators

  • Knight Therapeutics (USA) Inc

    lead INDUSTRY

Principal Investigators

  • Jaime Soto, MD · Fundacion Nacional de Dermatologia

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-02-23
Completion
2019-03-01

Countries

  • Bolivia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02431429 on ClinicalTrials.gov